Kliničke studije za Meningiom u državi Florida
7 studija za Meningiom traži sudionike na lokacijama u državi Florida.
Gradovi u državi Florida
Službeni tekst studije (engleski)
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- Boca Raton Regional Hospital, Boca Raton
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach
- Holy Cross Hospital, Fort Lauderdale
- i još 6
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT02523014Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
- Baptist MD Anderson Cancer Center, Jacksonville
- University of Miami, Miami
- Baptist Health Medical Group Oncology, Miami
- i još 1
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06955169A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
- Mayo Clinic_Jacksonville, Jacksonville
- Baptist Health Miami Cancer Institute, Miami
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT07428616Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
- University of Miami, Miami
U tijeku regrutacijaFaza 2
Od 12 godina i više · Oba spola · Ažurirano 2. ruj 2026. · NCT04374305Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
- BayCare Health, Clearwater
- Ascension St. Vincent's, Jacksonville
- Miami Cancer Institute, Baptist Health South Florida, Miami
- i još 4
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 22. srp 2026. · NCT04427384Cabozantinib for Patients With Recurrent or Progressive Meningioma
- Miami Cancer Institute at Baptist Health, Inc., Miami
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 14. svi 2026. · NCT05425004Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- Mayo Clinic, Jacksonville
- Biogenix Molecular, Miami
U tijeku regrutacijaFaza 1/2
Od 18 do 90 godina · Oba spola · Ažurirano 14. svi 2026. · NCT05636618Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.